# Beijing VDJBio Co., LTD.: Phase 3 study in Anti IL-6R, Castleman's Disease, Multicentric (45 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Beijing VDJBio Co., LTD. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease |
| NCT ID | NCT07872423 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Anti IL-6R; Castleman's Disease, Multicentric |
| Intervention types | drug |
| Target enrollment | 45 |
| Site countries | China |
| Posted | 2026-10-13 |
| Planned start | 2025-01-27 |
| Event | Newly registered study |
| Event date | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07872423). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.